These ain’t for the faint of heart, mind you. They’re for those who believe a little leverage can turn a decent profit into a king’s ransom, or, just as likely, turn a small loss into a rather substantial hole in the pocketbook. Let’s have a look at how these two stack up, shall we?
Doctors patch you up. That’s the theory. But what happens when you walk out the door? That’s where the real battle is fought. Bad habits, prescription costs that could choke a horse, a lack of exercise…it’s a long list. Omada tries to fill the gaps. Their app, apparently, is getting some traction. Forty thousand monthly downloads. That’s a number. They offer coaches, therapists, even video calls. It’s a digital band-aid for a system that’s already coming unglued.
Which means, anything that is actually going up this year deserves a second look. And wouldn’t you know it? Target. Yes, Target. The one everyone wrote off. Down 55% from its peak, and yet… up 22% year to date. Seriously? It’s like watching a slightly tragic, but determined, underdog in a rom-com. And I’m starting to feel a little bit invested.
Veeva, it turns out, doesn’t sell cleaning products or menace the galaxy. It provides cloud-based solutions specifically for the life sciences industry. Which, when you think about it, is rather clever. Focusing on a niche. It’s a bit like deciding to sell only left-handed golf clubs – a smaller market, certainly, but one with potentially less… interference. The demand for new drugs and medical gadgets isn’t exactly going to diminish anytime soon, is it? Especially with a global population that seems determined to get older, and a corresponding increase in the need for, well, everything. Veeva, in effect, is selling shovels to the gold miners of the pharmaceutical world.
Nvidia, the name now spoken with a reverence once reserved for the titans of the railways, finds itself at the heart of this undertaking. A single company, holding a disproportionate share of the market’s breath – over seven percent of the S&P 500. One watches, not with envy, but with a quiet apprehension. The large cloud-builders, already reaching for debt, are now poised on a precipice. This spending, this relentless expansion, cannot continue indefinitely. The memory of vanished empires, of fortunes built on sand, lingers like a scent on the wind.
The weight of these shares, calculated at a weighted average of $213.03, speaks not merely of capital, but of commitment – or, rather, the recalibration of it. It is a story told in numbers, yet feels strangely…personal. One wonders, as the sun dips below the horizon, what prompted this particular thinning of the branches.
To forestall the inevitable robotic uprising (or, more likely, a slightly irritating series of pop-up notifications), Microsoft has appointed Charlie Bell to oversee product quality. A sensible precaution. It’s like hiring a lighthouse keeper to watch over a fleet of self-navigating ships, really. You know, just in case. (The ships, of course, will claim they don’t need a lighthouse. They have algorithms. Algorithms are always right. Except when they’re not.)
Everyone speaks, of course, of the triumvirate: Coca-Cola, American Express, and Apple. Stocks practically glowing with an almost unseemly health. But allow me to draw your attention to a smaller, quieter holding, a position that, while comprising a mere 3.6% of the portfolio, possesses a peculiar… resilience. I speak of Moody’s. A name that evokes images of dusty ledgers and the solemn pronouncements of men who decide the fate of nations with a flick of a pen. A rather ominous occupation, when one considers the general state of things.
Now, before you start picturing Ms. FitzGerald making a beeline for the Bahamas, let’s unpack this a little. The sale represented about 11% of her direct holdings. Not nothing, certainly, but hardly a wholesale abandonment of ship. And, crucially, this wasn’t a spontaneous decision, but part of a pre-arranged plan – a “Rule 10b5-1 trading plan,” to be precise. It sounds terribly complicated, and frankly, it is, but the gist is that it allows company insiders to sell shares at pre-determined times and prices, avoiding the appearance of acting on inside information. It’s a bit like setting a timer on a toaster – you’re ensuring things happen when they’re supposed to, and not because you suddenly felt a craving for toast.
Investors, bless their frantic hearts, are perpetually drawn to the obvious. They chase the shimmering mirage of immediate gratification, while a more substantial reward often lies hidden in the shadows. It is with this in mind that I direct your attention to Micron Technology. A name, admittedly, less glamorous than Nvidia, but possessed of a peculiar, almost spectral, importance.